CTLA4 and cancer: A higher CD8/Treg ratio in ISF35+anti-CTLA-4+anti-PD-1-treated mice tumors support the notion that a higher CD8/Treg ratio is associated with better treatment efficacy and a favorable clinical outcome in preclinical models and cancer patients27, 28.